Navigation Links
Irinotecan in Medical News

Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection

BEDFORD, Ohio, Jan. 29 /PRNewswire-FirstCall/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the launch of Irinotecan HCl Injection. This product is AP rated and is equivalent to Camptosar(R). Irinotecan is indicated for patients with metastatic carcinoma o...

Hospira Launches Generic Irinotecan Injection

- Offers Unique Formulation of Important Cancer Medication - LAKE FOREST, Ill., Feb. 27 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced the launch of irinotecan hydrochloride injection in the United States. Th...

Genetic testing may be valuable in treating colorectal cancer

...s in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for mo...al care, patients received a full dose of irinotecan. With genetic testing, irinotecan dosage was reduced 25 percent in individuals identified using the genetic t...

NCCN Updates Guidelines for Central Nervous System (CNS) Cancers

... aggressive type of primary brain tumor, the updated NCCN Guidelines now recommend bevacizumab (Avastin(R), Genentech/Roche) as a single agent without irinotecan (Camptosar(R), Pfizer) for recurrence/salvage therapy. Previously, bevacizumab was only an option when used in combination with irinotecan. Anoth...

Amgen Highlights Data to Be Presented at ASCO

...thor: Rougier P Abstract No. 4130 (Sunday, May 31, 2009, 8:00am-12:00pm) Phase 1b study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results Lead Author: Yee L Abstract No....

Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research

...ard 1). AACR Abstract #4578: Tardi P, Harasym T, Bermudes D, et al. CPX-1, a liposome formulation containing a synergistic 1:1 molar ratio of irinotecan and floxuridine, exhibits increased efficacy in combination with either bevacizumab (BEV) or cetuximab (CET) in human colorectal cancer (CRC) solid tu...

Screening the herbal pharmacy

...front yards, is the source of vinca alkaloids that are effective, for example, against malignant lymphomas. The modern anti-cancer drugs topotecan and irinotecan are derived from a constituent of the Chinese Happy Tree. Looking for new compounds, doctors and scientists are increasingly focusing on substance...

Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits

...mized, controlled, multi-center phase III trial of 829 patients with advanced or metastatic colorectal cancer who had received previous treatment with irinotecan and 5-FU as initial therapy for metastatic disease or as adjuvant therapy. The study showed that patients who received Avastin plus the 5-FU-based che...

Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York

...bination with standard cetuximab as a second-line colorectal cancer treatment in irinotecan-naive patients as compared to treatment with cetuximab and irinotecan alone. The open label, randomized, double-arm study is planned to be conducted at over 40 centers in the U.S. and the European Union. NKTR-102 is curr...

Gene screen patent leads to 'Deal of Distinction'

...ry alone. Many colorectal cancer patients receive a first-line treatment of irinotecan hydrochloride (Camptosar(r)). Still in its early phases of implementation, ...elps metabolize the drug. Patients who are at risk receive reduced doses of irinotecan hydrochloride or are treated with other chemotherapy drugs. "This is a l...
Irinotecan in Medical Technology

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...tages of colorectal cancer. Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...tages of colorectal cancer. Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda(R)), irinotecan (Camptosar(R)), oxaliplatin (Eloxatin(R)), bevacizumab (Avastin(R)), cetuximab (Erbitux(R)), and panitumumab (Vectibix(R)). Depending on the stage of...

Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer

...ntreated animals, and was significantly better than all controls, including irinotecan administered at its maximum tolerated dose, which is a 50-fold increase in ...e bioavailability and reduce the toxicity of the clinically validated drug, irinotecan , " commented Cynthia L. Sullivan, President and CEO. "More preclinical ev...

Chemoembolization Improving as Liver Cancer Treatment

...liver cancer patients and 10 of the 13 (77 percent) of the colorectal patients were alive after two years. Conversely, one of 12 (8.3 percent) of the irinotecan patients were alive after two years. Researchers are studying why doxorubicin appears to work better in these cases. LC Beads slowly elute the c...

Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer

.... These data compare favorably to results published from other studies with irinotecan or an irinotecan-based regimen in this patient population which report an a...cetuximab monotherapy). Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and flu...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

...meaningful improvement in progression-free survival as compared to standard irinotecan monotherapy. "With these recent clinical studies on K-Ras, there is no lo...y in a Phase 2a study to evaluate NKTR-102 in combination with cetuximab. irinotecan is an important chemotherapeutic agent used for the treatment of solid tumo...

Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer

...onstrates that Avastin is highly active and also well tolerated for CRC patients with yet further chemotherapy combinations, Xeloda (capecitabine) and irinotecan (XELIRI) and Xeloda and oxaliplatin (XELOX). This data reinforces that Avastin is first choice for the treatment of patients with CRC and that it can ...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

...e that was up to six-fold higher than the exposure previously reported with irinotecan at equivalent doses. SN38, a topoisomerase I inhibitor, is the active metab...elopment to evaluate its efficacy and safety in combination with cetuximab. irinotecan is an important chemotherapeutic agent used for the treatment of solid tumo...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

...ofile and tolerability of NKTR-102, as compared to irinotecan in animal models. NKTR-102 is a PEGylated form of irinotecan developed using Nektar's innovative small molecule...d safety and tolerability profile when compared to irinotecan in animal models. Both the incidence and severity ...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

...novel PEGylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing" Poster #5742: "NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety, tolerability, and pharmacokinet...
Irinotecan in Biological News

Experimental chemotherapy regimen shows promise in treating advanced lung cancer

...th an advanced form of this common lung cancer, endpoints including response rate, progression-free survival, and overall survival from use of S-1 and irinotecan were similar to, or better than, those reported from standard treatment with platinum-based chemotherapy regimens. Because the study had only a sin...

UNC study questions FDA genetic-screening guidelines for cancer drug

...ate to test all patients before treating them with irinotecan even though many clinicians didnt think it was alw...ded that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patien...
Irinotecan in Biological Technology

Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product

MORRISTOWN, N.J., Feb. 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, has received approval for Irinotecan Hydrochloride Injection from the U.S. Food & Drug Administration. Distribution of the product will begin immediately. Irinotecan Hydrochloride Inje...

Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary CombiPlex(TM) technology platform. PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive re...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

...andomized, open-label trial they are conducting evaluating nimotuzumab plus irinotecan compared to irinotecan alone in patients with advanced or recurrent gastric cancer who are refract...

Patent for Making Combination Chemotherapy Work Better

...s are provided. All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typic...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

...ndomized Phase 2 study to evaluate NKTR-102 versus irinotecan in second-line colorectal cancer patients with the...efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line colorectal cancer patients with the... progression-free survival as compared to standard irinotecan monotherapy. It is estimated that up to 45% of co...

ScinoPharm Granted US Patent for Novel Crystal Forms

...from solution as compared to the existing forms of irinotecan hydrochloride. This increased ease of filtering promotes more efficient handling and processing of irinotecan hydrochloride during the manufacturing process, th...improved pharmaceutical compositions which contain irinotecan hydrochloride. "That we were awarded a US ...

Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium

...y, which includes additional indications for which irinotecan was never developed, such as ovarian, cervical, an...er than the observed half-life of 30-50 hours with irinotecan dosing.(1) Increased SN38 levels, the active metabolite of irinotecan responsible for its anti-tumor activity, were also...

Lilly to Acquire ImClone Systems in $6.5 Billion Transaction

.... The effectiveness of ERBITUX in combination with irinotecan is based on objective response rates. Currently, n...ncreased survival with ERBITUX in combination with irinotecan for the treatment of EGFR-expressing metastatic co...olorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater than or equa...

Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer

...se I/II Study of Zalutumumab in Combination With irinotecan Chemotherapy to Treat Refractory Colorectal ...f zalutumumab (HuMax-EGFr(TM)) in combination with irinotecan chemotherapy to treat colorectal cancer (CRC). The...kly doses of zalutumumab with or without bi-weekly irinotecan administration until disease progression. In total...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL

...s in two 50-patient cohorts, consecutively, with the first cohort receiving irinotecan and weekly dosing of nimotuzumab and the second cohort receiving irinotecan with nimotuzumab every two weeks. The endpoints of the trial include the ra...
Other Tags
(Date:2/27/2015)... (PRWEB) February 27, 2015 Royal River Natural ... reports a new study that found adults who got the ... type 2 diabetes compared to those who got the least ... sugar levels. , The report is part of the March ... which Royal River Natural Foods publishes free each month for ...
(Date:2/27/2015)... February 27, 2015 On February 24 2015, ... Liquid Botox ,” that details the development of RT001, ... working its way through FDA trials. For those afraid of ... is very attractive. Of course, if the drug ultimately gets ... a physician’s office. (see: goo.gl/PQvQwk) , “As the article notes, ...
(Date:2/27/2015)... Winter is here, and with it comes ... to snow and ice can be harmful on a dog’s ... The Puppy Store is ready to help pet owners know ... in the winter time. , Ice melts can lead to ... symptoms. Ingestion of ice melt products may cause depression, loss ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Victorian Hotel ... deals for couples who wanted to spend the auspicious ... opportunity to get a jump on Valentine’s Day with ... stay in one of their luxurious rooms. , ... 13, inviting guests for a mouthwatering 3 course meal ...
(Date:2/27/2015)... February 27, 2015 Mediaplanet today announces ... Health,” a campaign that aims to bring blood health ... care conversation. The stories in this edition go beyond ... of clinical care, hard-hitting advocacy, research and technological strides ... According the American Cancer Society, approximately every 3 ...
Breaking Medicine News(10 mins):Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Is Topical Botox the Next Big Thing? 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
Other Contents